Takeda is the largest pharmaceutical company in Japan and a global leader in rare disease and oncology and one of the world's leading biotechnology companies.
Takeda generated approximately $30 billion in annual revenue in 2025, making it the largest pharmaceutical company in Japan and one of the top 15 globally. The company's strategic identity was transformed by the $62 billion acquisition of Shire in 2019 — the largest acquisition in Japanese corporate history — which added the world's leading rare disease portfolio spanning hereditary angioedema, Fabry disease, Gaucher disease, Hunter syndrome, and rare hematology. Takeda's plasma-derived therapy business — inherited from Shire's Baxalta unit — is one of the three largest globally. The company's oncology portfolio, neuroscience pipeline, and gastrointestinal franchise round out a diversified product portfolio across six therapeutic areas.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Takeda — Key Financial Metrics 2023-2025
Table 2. Takeda — Revenue by Product 2023-2025
Table 3. Takeda — Revenue by Geography 2023-2025
Table 4. Takeda — R&D Investment 2023-2025
Table 5. Takeda — SWOT Analysis
Table 6. Takeda — Key Products and Pipeline 2025
Table 7. Takeda — M&A Activity 2020-2025
Table 8. Takeda — Key Management 2025
Table 9. Takeda — Strategic Priorities 2025-2030
